lm11a-31-bhs
Small moleculeexperimental
Clinical trial activity
2 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 15, 2017 (NCT03069014)
Timeline
Indications
Studied for
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- lm11a-31-bhs
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07264283 | Phase 2 | Dec 1, 2025 | Alzheimer's Clinical Trial Consortium (ACTC), Alzheimer's Therapeutic Research Institute, Harvard University, National Institute on Aging (NIA), PharmatrophiX Inc., University of California, San Diego, University of California, San Francisco, University of Southern California |
| NCT03069014 | Phase 1/Phase 2 (Phase 2) | Feb 15, 2017 | National Institute on Aging (NIA), NeuroScios GmbH, PharmatrophiX Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute on Aging (NIA) | Government | 2 | 0 | 1 | 2017 |
| PharmatrophiX Inc. | For profit | 2 | 1 | 1 | 2017 |
| Alzheimer's Clinical Trial Consortium (ACTC) | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Alzheimer's Therapeutic Research Institute | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| NeuroScios GmbH | For profit | 1 | 0 | 1 | 2017 |
| University of California, San Diego | Academic/Hospital | 1 | 0 | 1 | 2025 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of Southern California | Academic/Hospital | 1 | 0 | 1 | 2025 |
9 organizations
Page 1 / 1